June 18 - CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
June 3 - Paclitaxel Poliglumex (OPAXIO™)/Capecitabine Regimen Well Tolerated and Active in Metastatic Breast Cancer
June 2 - Investigational Studies Highlight Potential Utility of Zevalin® (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma
More Press Releases
